We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
21 Jun 2021 - 24 Jun 2021

Tissue Counterpart to Monoclonal B-Cell Lymphocytosis Characterized

By LabMedica International staff writers
Posted on 21 Apr 2021
Print article
Image: BD FACSCanto II flow cytometer (Photo courtesy of BD Biosciences)
Image: BD FACSCanto II flow cytometer (Photo courtesy of BD Biosciences)
Monoclonal B-cell lymphocytosis (MBL) was initially proposed to recognize patients with a monotypic B cell population identified by peripheral blood (PB) flow cytometry (FC) that did not meet numerical criteria for chronic lymphocytic leukemia (CLL).

While MBL is defined in the blood, pathologists encounter rare cases in which a monotypic B-cell population is detected in biopsy tissue undergoing FC without obvious morphologic involvement by lymphoma (referred to as tMBL). Most, if not all, cases of CLL are preceded by MBL.

Medical Laboratory Scientists at the Cleveland Clinic (Cleveland, OH, USA) retrospectively identified non–bone marrow/peripheral blood cases with monotypic B cells detected by tissue-based flow cytometry, but without an identifiable lymphomatous infiltrate on routine histopathology during a 10 year period. They excluded cases with prior diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma or MBL. Flow cytometry was performed in-house on 31 cases (6-color FC, 0.04% sensitivity; BD FACSCanto, (BD Biosciences, San Jose, CA, USA) or was performed at outside reference laboratories.

The scientists identified 54 cases (35 lymph node, three splenic, and 16 soft tissue/viscera). Forty-six cases were CLL-type, two were atypical CLL, and six were non-CLL. tMBL was detectable by immunohistochemistry in 14 cases (26%, all CLL-type). Concurrent blood flow cytometry, available in 10 cases, showed four with low-count MBL (3 CLL-type, one with non-CLL–type), five with high-count MBL (all CLL-type), and one case negative for clonal population. With median follow-up of 51 months, two patients had progression of disease (CLL, 68.7 months; and diffuse large B-cell lymphoma, 5.9 months). Patients with immunohistochemistry-detectable tMBL had increased monoclonal B cells per total lymphocyte events, morphologic evidence of bone marrow involvement, higher white blood cell count, and increased absolute lymphocyte count.

The authors concluded that tMBL spans an immunophenotypic spectrum similar to MBL, is detectable by immunohistochemistry in a minority of cases (often CLL immunophenotype), and is likely systemic in most cases. Development of overt lymphoma is uncommon but may occur, warranting clinical follow-up. The study was published on March 15, 2021 in the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Cleveland Clinic
BD Biosciences

Gold Supplier
SARS-CoV-2 Antibody Test
SARS-CoV-2 Nucleoprotein IgG Antibody ELISA Kit
SARS-CoV-2 Nucleoprotein IgG Antibody ELISA Kit
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software
Infant Heel Lancet
Unistik TinyTouch

Print article
BIOHIT  Healthcare OY


Clinical Chem.

view channel
Image: Blood test for  plasma aldosterone concentration was used to screen For hyperaldosteronism in hypertensive men (Photo courtesy of  VisitHealth Ltd)

Urinary Sodium/Potassium Ratio Screens for Hyperaldosteronism in Hypertensive Men

Among individuals with hypertension, the prevalence of secondary hypertension has been reported to be around 10%. More than half of individuals with secondary hypertension have associated hyperaldosteronism.... Read more


view channel

Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028

The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.